U.S. patent application number 17/514781 was filed with the patent office on 2022-02-17 for negative-pressure therapy with disposable instillation pump chamber.
The applicant listed for this patent is KCI Licensing, Inc.. Invention is credited to Christopher Brian LOCKE, James A. LUCKEMEYER, Benjamin Andrew PRATT.
Application Number | 20220047798 17/514781 |
Document ID | / |
Family ID | |
Filed Date | 2022-02-17 |
United States Patent
Application |
20220047798 |
Kind Code |
A1 |
LUCKEMEYER; James A. ; et
al. |
February 17, 2022 |
NEGATIVE-PRESSURE THERAPY WITH DISPOSABLE INSTILLATION PUMP
CHAMBER
Abstract
Systems, apparatuses, and methods for instilling fluid to a
tissue site in a negative-pressure therapy environment are
described. Illustrative embodiments may include a
pneumatically-actuated instillation pump that can draw a solution
from a solution source during a negative-pressure interval, and
instill the solution to a dressing during a venting interval. A
pneumatic actuator may be mechanically coupled to a disposable
distribution system that can provide a fluid path between the
solution source and a distribution component. A bacterial filter
may be disposed in the fluid path between the actuator and the
distribution component to prevent contamination of the actuator
during operation. The distribution system may be separated from the
actuator and disposed of after operation, and the actuator may be
re-used.
Inventors: |
LUCKEMEYER; James A.; (San
Antonio, TX) ; LOCKE; Christopher Brian;
(Bournemouth, GB) ; PRATT; Benjamin Andrew;
(Poole, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
KCI Licensing, Inc. |
San Antonio |
TX |
US |
|
|
Appl. No.: |
17/514781 |
Filed: |
October 29, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16302585 |
Nov 16, 2018 |
11185624 |
|
|
PCT/US2017/032917 |
May 16, 2017 |
|
|
|
17514781 |
|
|
|
|
62345368 |
Jun 3, 2016 |
|
|
|
International
Class: |
A61M 1/00 20060101
A61M001/00 |
Claims
1-16. (canceled)
17. A system for providing negative-pressure and instillation
therapy, the system comprising: a negative-pressure source
configured to provide a negative-pressure interval and a venting
interval; an actuator comprising a pneumatic cylinder; and a
distribution system comprising a dosing chamber, a fluid port
configured to be fluidly coupled to the dosing chamber and to the
negative-pressure source, and a fluid fitting configured to couple
the pneumatic cylinder to the fluid port; wherein the actuator is
configured to expand the dosing chamber during the
negative-pressure interval and contract the dosing chamber during
the venting interval.
18. The system of claim 17, wherein the distribution system
comprises a bacterial filter between the fluid port and the fluid
fitting.
19. The system of claim 17, wherein the distribution system
comprises a constriction between the dosing chamber and the fluid
port.
20. The system of claim 17, further comprising a solution source
fluidly coupled to the dosing chamber.
21. The system of claim 17, wherein the distribution system further
comprises: a first check valve fluidly coupled to the dosing
chamber; and a second check valve fluidly coupled to the dosing
chamber and to the fluid port.
22. The system of claim 17, wherein the distribution system further
comprises: a first fluid conductor between the dosing chamber and
the fluid port; and a second fluid conductor between the fluid
fitting and the fluid port.
23. The system of claim 17, wherein the dosing chamber comprises a
bellows.
24. The system of claim 17, wherein the dosing chamber comprises a
rolling diaphragm.
25. The system of any of claim 17, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
26. (canceled)
27. (canceled)
28. The system of any of claim 18, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
29. The system of any of claim 19, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
30. The system of any of claim 20, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
31. The system of any of claim 21, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
32. The system of any of claim 22, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
33. The system of any of claim 23, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
34. The system of any of claim 24, wherein the actuator further
comprises a clamp between the dosing chamber and the fluid port,
and the actuator is configured to close the clamp under negative
pressure.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 16/302,585, filed Nov. 16, 2018, which is a U.S. National
Phase Entry of International Patent Application No.
PCT/US2017/032917, filed May 16, 2017, which claims the benefit,
under 35 USC .sctn. 119(e), of the filing of U.S. Provisional
Patent Application No. 62/345,368, entitled "Negative-Pressure
Therapy With Disposable Instillation Pump Chamber" filed Jun. 3,
2016, which are incorporated herein by reference for all
purposes.
TECHNICAL FIELD
[0002] The invention set forth in the appended claims relates
generally to tissue treatment systems and more particularly, but
without limitation, to apparatuses and methods for providing
negative-pressure therapy with instillation of topical treatment
solutions.
BACKGROUND
[0003] Clinical studies and practice have shown that reducing
pressure in proximity to a tissue site can augment and accelerate
growth of new tissue at the tissue site. The applications of this
phenomenon are numerous, but it has proven particularly
advantageous for treating wounds. Regardless of the etiology of a
wound, whether trauma, surgery, or another cause, proper care of
the wound is important to the outcome. Treatment of wounds or other
tissue with reduced pressure may be commonly referred to as
"negative-pressure therapy," but is also known by other names,
including "negative-pressure wound therapy," "reduced-pressure
therapy," "vacuum therapy," "vacuum-assisted closure," and "topical
negative-pressure," for example. Negative-pressure therapy may
provide a number of benefits, including migration of epithelial and
subcutaneous tissues, improved blood flow, and micro-deformation of
tissue at a wound site. Together, these benefits can increase
development of granulation tissue and reduce healing times.
[0004] There is also widespread acceptance that cleansing a tissue
site can be highly beneficial for new tissue growth. For example, a
wound can be washed out with a stream of liquid solution, or a
cavity can be washed out using a liquid solution for therapeutic
purposes. These practices are commonly referred to as "irrigation"
and "lavage" respectively. "Instillation" is another practice that
generally refers to a process of slowly introducing fluid to a
tissue site and leaving the fluid for a prescribed period of time
before removing the fluid. For example, instillation of topical
treatment solutions over a wound bed can be combined with
negative-pressure therapy to further promote wound healing by
loosening soluble contaminants in a wound bed and removing
infectious material. As a result, soluble bacterial burden can be
decreased, contaminants removed, and the wound cleansed.
[0005] While the clinical benefits of negative-pressure therapy and
instillation therapy are widely known, improvements to therapy
systems, components, and processes may benefit healthcare providers
and patients.
BRIEF SUMMARY
[0006] New and useful systems, apparatuses, and methods for
instilling fluid to a tissue site in a negative-pressure therapy
environment are set forth in the appended claims. Illustrative
embodiments are also provided to enable a person skilled in the art
to make and use the claimed subject matter. Some embodiments are
illustrative of an apparatus or system for delivering therapeutic
solution of fluids to a tissue site, which can be used in
conjunction with negative-pressure therapy. For example, an
apparatus may include a pneumatically-actuated instillation pump
that can draw a solution from a solution source during a
negative-pressure interval, and instill the solution to a dressing
during a venting interval.
[0007] In some embodiments, for example, a pneumatic actuator may
be mechanically coupled to a disposable distribution system. The
distribution system may generally comprise a dosing chamber, and
one or more fluid conductors that can provide a fluid path between
the dosing chamber and a solution source, and between the dosing
chamber and a distribution component, such as a dressing or
dressing interface. One or more fluid conductors may also provide a
fluid path between the actuator and a distribution component. A
bacterial filter may be disposed in the fluid path between the
actuator and the distribution component to prevent contamination of
the actuator during operation. The distribution system may be
separated from the actuator and disposed of after operation, and
the actuator may be re-used.
[0008] More generally, some embodiments of an apparatus for
managing fluid in a system for negative-pressure therapy may
include a dosing chamber having a fluid inlet and a fluid outlet. A
first check valve may be fluidly coupled to the fluid inlet, and a
second check valve may be fluidly coupled to the fluid outlet. A
fluid conductor can be fluidly coupled to the second check valve,
and a fluid fitting can be fluidly coupled to the fluid conductor.
A fluid port fluidly coupled to the fluid conductor can be
configured to be coupled to a negative-pressure source, and a
filter fluidly coupled to the fluid conductor between the fluid
port and the fluid fitting can prevent contamination of other
components. In some embodiments, the fluid conductor may comprise a
constriction, and the filter is preferably a bacterial filter.
[0009] In more specific examples, the fluid port may comprise or
consist essentially of a dressing pad configured to be coupled to a
dressing, which can be applied to a tissue site. The fluid
conductor may comprise a first conductor and a second conductor in
some embodiments, and the fluid port can fluidly couple the first
conductor to the second conductor. The apparatus may further
include a liquid coupling, such as a spike connector, configured to
couple the dosing chamber to a solution source. In some
embodiments, the apparatus may additionally or alternatively
include a solution source.
[0010] The apparatus may additionally include an instillation
actuator in some embodiments. Such an instillation actuator may be
fluidly coupled to the fluid fitting and mechanically coupled to
the dosing chamber. The fluid coupling and the mechanical coupling
are both preferably temporary couplings, adapted to allow the
instillation actuator to be routinely coupled to and removed from
the fluid fitting and the dosing chamber without compromising the
integrity of any components. The instillation actuator may be
configured to expand and contract the dosing chamber. For example,
in some embodiments, the instillation actuator may comprise a
piston chamber and a piston operably engaged to the dosing chamber.
Pressure changes in the piston chamber can actuate the piston to
expand and contract the dosing chamber. In some embodiments,
expansion of the dosing chamber can draw solution into the dosing
chamber, and contraction of the dosing chamber can expel the
solution from the dosing chamber.
[0011] In some example embodiments, the apparatus may further
comprise a negative-pressure source fluidly coupled to the fluid
port. The negative-pressure source may provide negative-pressure
intervals and venting intervals. In operation, the instillation
actuator can expand the dosing chamber during a negative-pressure
interval to draw a dose of solution from a solution source, and can
contract the dosing chamber during a venting interval to expel the
dose of solution from the dosing chamber to a dressing or other
distribution component.
[0012] Alternatively, other example embodiments may include a
system for providing negative-pressure and instillation therapy.
The system may include a negative-pressure source configured to
provide a negative-pressure interval and a venting interval, an
actuator, and a distribution system. The actuator may comprise a
pneumatic cylinder, and the distribution system may comprise a
dosing chamber, a fluid port, and a fluid fitting in some
embodiments. The fluid port may be configured to be fluidly coupled
to the dosing chamber and to the negative-pressure source, and the
fluid fitting can couple the pneumatic cylinder of the actuator to
the fluid port. The actuator is preferably configured to expand the
dosing chamber during the negative-pressure interval and contract
the dosing chamber during the venting interval. In more specific
examples, the distribution system may additionally include a
bacterial filter between the fluid port and the fluid fitting.
[0013] A method for managing fluid in a therapy system may include
fluidly coupling an apparatus or system as described to a dressing,
which can be applied to a tissue site. Negative pressure may be
applied to the tissue site for a first interval, in which
instillation solution may be drawn into the dosing chamber.
Negative pressure may be vented from the tissue site for a second
interval, in which instillation solution can be delivered from the
apparatus to the tissue site.
[0014] Objectives, advantages, and a preferred mode of making and
using the claimed subject matter may be understood best by
reference to the accompanying drawings in conjunction with the
following detailed description of illustrative embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] FIG. 1 is a functional block diagram of an example
embodiment of a therapy system that can provide negative-pressure
and instillation in accordance with this specification;
[0016] FIG. 2 is a schematic diagram illustrating additional
details of a distribution system that may be associated with some
example embodiments of the therapy system of FIG. 1;
[0017] FIG. 3A is a schematic diagram illustrating additional
details that may be associated with some embodiments of an
instillation pump during a negative-pressure interval;
[0018] FIG. 3B is a schematic diagram illustrating additional
details that may be associated with some embodiments of an
instillation pump during a venting interval;
[0019] FIG. 4 is a schematic diagram illustrating additional
details of another example distribution system that may be
associated with some embodiments of the therapy system of FIG.
1;
[0020] FIG. 5A is a schematic diagram illustrating additional
details that may be associated with other example embodiments of an
instillation pump during a negative-pressure interval; and
[0021] FIG. 5B is a schematic diagram illustrating additional
details that may be associated with other example embodiments of an
instillation pump during a venting interval.
DESCRIPTION OF EXAMPLE EMBODIMENTS
[0022] The following description of example embodiments provides
information that enables a person skilled in the art to make and
use the subject matter set forth in the appended claims, but may
omit certain details already well-known in the art. The following
detailed description is, therefore, to be taken as illustrative and
not limiting.
[0023] The example embodiments may also be described herein with
reference to spatial relationships between various elements or to
the spatial orientation of various elements depicted in the
attached drawings. In general, such relationships or orientation
assume a frame of reference consistent with or relative to a
patient in a position to receive treatment. However, as should be
recognized by those skilled in the art, this frame of reference is
merely a descriptive expedient rather than a strict
prescription.
[0024] FIG. 1 is a simplified functional block diagram of an
example embodiment of a therapy system 100 that can provide
negative-pressure therapy with instillation of topical treatment
solutions to a tissue site in accordance with this
specification.
[0025] The term "tissue site" in this context broadly refers to a
wound, defect, or other treatment target located on or within
tissue, including but not limited to, bone tissue, adipose tissue,
muscle tissue, neural tissue, dermal tissue, vascular tissue,
connective tissue, cartilage, tendons, or ligaments. A wound may
include chronic, acute, traumatic, subacute, and dehisced wounds,
partial-thickness burns, ulcers (such as diabetic, pressure, or
venous insufficiency ulcers), flaps, and grafts, for example. The
term "tissue site" may also refer to areas of any tissue that are
not necessarily wounded or defective, but are instead areas in
which it may be desirable to add or promote the growth of
additional tissue. For example, negative pressure may be applied to
a tissue site to grow additional tissue that may be harvested and
transplanted.
[0026] The therapy system 100 may include a negative-pressure
supply, and may include or be configured to be coupled to a
distribution component, such as a dressing. In general, a
distribution component may refer to any complementary or ancillary
component configured to be fluidly coupled to a negative-pressure
supply between a negative-pressure supply and a tissue site. A
distribution component is preferably detachable, and may be
disposable, reusable, or recyclable. For example, a dressing 102 is
illustrative of a distribution component fluidly coupled to a
negative-pressure source 104 in FIG. 1. A dressing may include a
cover, a tissue interface, or both in some embodiments. The
dressing 102, for example, may include a cover 106 and a tissue
interface 108. A regulator or a controller, such as a controller
110, may also be coupled to the negative-pressure source 104.
[0027] In some embodiments, another distribution component, such as
a dressing interface, may facilitate coupling the negative-pressure
source 104 to the dressing 102. For example, a dressing interface
may be a T.R.A.C..RTM. Pad or Sensa T.R.A.C..RTM. Pad available
from KCI of San Antonio, Tex. The therapy system 100 may optionally
include a fluid container, such as a container 112, coupled to the
dressing 102 and to the negative-pressure source 104.
[0028] The therapy system 100 may also include a source of
instillation solution, such as a solution source 114. A
distribution component may be fluidly coupled to a fluid path
between a solution source and a tissue site in some embodiments.
For example, an instillation pump 116 may be coupled to the
solution source 114, as illustrated in the example embodiment of
FIG. 1. In some embodiments, the instillation pump 116 may comprise
an actuator, such as an instillation actuator 118, and a pump
chamber, such as a dosing chamber 120. For example, the dosing
chamber 120 may be fluidly coupled to the solution source 114 and
to the dressing 102. The instillation actuator 118 may be coupled
to the dosing chamber 120 in some embodiments. In FIG. 1, for
example, the instillation actuator 118 may be mechanically coupled
to the dosing chamber 120. The instillation actuator 118 may also
be fluidly coupled to the negative-pressure source 104. In some
embodiments, the instillation actuator 118 may be directly coupled
to the negative-pressure source 104, as illustrated in FIG. 1, but
may be indirectly coupled to the negative-pressure source 104
through other distribution components in some embodiments. For
example, in some embodiments, the instillation actuator 118 may be
fluidly coupled to the negative-pressure source 104 through the
dressing 102
[0029] Additionally, the therapy system 100 may include sensors to
measure operating parameters and provide feedback signals to the
controller 110 indicative of the operating parameters. As
illustrated in FIG. 1, for example, the therapy system 100 may
include a pressure sensor 122, an electric sensor 124, or both,
coupled to the controller 110. The pressure sensor 122 may also be
coupled or configured to be coupled to a distribution component and
to the negative-pressure source 104.
[0030] Components may be fluidly coupled to each other to provide a
distribution system for transferring fluids (i.e., liquid and/or
gas). For example, a distribution system may include various
combinations of fluid conductors and fittings to facilitate fluid
coupling. A fluid conductor generally includes any structure with
one or more lumina adapted to convey a fluid between two ends, such
as a tube, pipe, hose, or conduit. Typically, a fluid conductor is
an elongated, cylindrical structure with some flexibility, but the
geometry and rigidity may vary. Some fluid conductors may be molded
into or otherwise integrally combined with other components. A
fitting can be used to mechanically and fluidly couple components
to each other. For example, a fitting may comprise a projection and
an aperture. The projection may be configured to be inserted into a
fluid conductor so that the aperture aligns with a lumen of the
fluid conductor. A valve is a type of fitting that can be used to
control fluid flow. For example, a check valve can be used to
substantially prevent return flow. A port is another example of a
fitting. A port may also have a projection, which may be threaded,
flared, tapered, barbed, or otherwise configured to provide a fluid
seal when coupled to a component.
[0031] In some embodiments, components may also be coupled by
virtue of physical proximity, being integral to a single structure,
or being formed from the same piece of material. Coupling may also
include mechanical, thermal, electrical, or chemical coupling (such
as a chemical bond) in some contexts. For example, a tube may
mechanically and fluidly couple the dressing 102 to the container
112 in some embodiments.
[0032] In general, components of the therapy system 100 may be
coupled directly or indirectly. For example, the negative-pressure
source 104 may be directly coupled to the controller 110, and may
be indirectly coupled to the dressing 102 through the container
112.
[0033] The fluid mechanics of using a negative-pressure source to
reduce pressure in another component or location, such as within a
sealed therapeutic environment, can be mathematically complex.
However, the basic principles of fluid mechanics applicable to
negative-pressure therapy and instillation are generally well-known
to those skilled in the art, and the process of reducing pressure
may be described illustratively herein as "delivering,"
"distributing," or "generating" negative pressure, for example.
[0034] In general, exudates and other fluids flow toward lower
pressure along a fluid path. Thus, the term "downstream" typically
implies something in a fluid path relatively closer to a source of
negative pressure or further away from a source of positive
pressure. Conversely, the term "upstream" implies something
relatively further away from a source of negative pressure or
closer to a source of positive pressure. Similarly, it may be
convenient to describe certain features in terms of fluid "inlet"
or "outlet" in such a frame of reference. This orientation is
generally presumed for purposes of describing various features and
components herein. However, the fluid path may also be reversed in
some applications (such as by substituting a positive-pressure
source for a negative-pressure source) and this descriptive
convention should not be construed as a limiting convention.
[0035] "Negative pressure" generally refers to a pressure less than
a local ambient pressure, such as the ambient pressure in a local
environment external to a sealed therapeutic environment provided
by the dressing 102. In many cases, the local ambient pressure may
also be the atmospheric pressure at which a tissue site is located.
Alternatively, the pressure may be less than a hydrostatic pressure
associated with tissue at the tissue site. Unless otherwise
indicated, values of pressure stated herein are gauge pressures.
Similarly, references to increases in negative pressure typically
refer to a decrease in absolute pressure, while decreases in
negative pressure typically refer to an increase in absolute
pressure. While the amount and nature of negative pressure applied
to a tissue site may vary according to therapeutic requirements,
the pressure is generally a low vacuum, also commonly referred to
as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7
kPa). Common therapeutic ranges are between -75 mm Hg (-9.9 kPa)
and -300 mm Hg (-39.9 kPa).
[0036] A negative-pressure supply, such as the negative-pressure
source 104, may be a reservoir of air at a negative pressure, or
may be a manual or electrically-powered device that can reduce the
pressure in a sealed volume, such as a vacuum pump, a suction pump,
a wall suction port available at many healthcare facilities, or a
micro-pump, for example. A negative-pressure supply may be housed
within or used in conjunction with other components, such as
sensors, processing units, alarm indicators, memory, databases,
software, display devices, or user interfaces that further
facilitate therapy. For example, in some embodiments, the
negative-pressure source 104 may be combined with the controller
110 and other components into a therapy unit. A negative-pressure
supply may also have one or more supply ports configured to
facilitate coupling and de-coupling the negative-pressure supply to
one or more distribution components.
[0037] The tissue interface 108 can be generally adapted to contact
a tissue site. The tissue interface 108 may be partially or fully
in contact with the tissue site. If the tissue site is a wound, for
example, the tissue interface 108 may partially or completely fill
the wound, or may be placed over the wound. The tissue interface
108 may take many forms, and may have many sizes, shapes, or
thicknesses depending on a variety of factors, such as the type of
treatment being implemented or the nature and size of a tissue
site. For example, the size and shape of the tissue interface 108
may be adapted to the contours of deep and irregular shaped tissue
sites. Moreover, any or all of the surfaces of the tissue interface
108 may have projections or an uneven, course, or jagged profile
that can induce strains and stresses on a tissue site, which can
promote granulation at the tissue site.
[0038] In some embodiments, the tissue interface 108 may be a
manifold. A "manifold" in this context generally includes any
substance or structure providing a plurality of pathways adapted to
collect or distribute fluid across a tissue site under pressure.
For example, a manifold may be adapted to receive negative pressure
from a source and distribute negative pressure through multiple
apertures across a tissue site, which may have the effect of
collecting fluid from across a tissue site and drawing the fluid
toward the source. In some embodiments, the fluid path may be
reversed or a secondary fluid path may be provided to facilitate
delivering fluid across a tissue site.
[0039] In some illustrative embodiments, the pathways of a manifold
may be interconnected to improve distribution or collection of
fluids across a tissue site. In some illustrative embodiments, a
manifold may be a porous foam material having interconnected cells
or pores. For example, cellular foam, open-cell foam, reticulated
foam, porous tissue collections, and other porous material such as
gauze or felted mat generally include pores, edges, and/or walls
adapted to form interconnected fluid channels. Liquids, gels, and
other foams may also include or be cured to include apertures and
fluid pathways. In some embodiments, a manifold may additionally or
alternatively comprise projections that form interconnected fluid
pathways. For example, a manifold may be molded to provide surface
projections that define interconnected fluid pathways.
[0040] The average pore size of a foam may vary according to needs
of a prescribed therapy. For example, in some embodiments, the
tissue interface 108 may be a foam having pore sizes in a range of
400-600 microns. The tensile strength of the tissue interface 108
may also vary according to needs of a prescribed therapy. For
example, the tensile strength of a foam may be increased for
instillation of topical treatment solutions. In one non-limiting
example, the tissue interface 108 may be an open-cell, reticulated
polyurethane foam such as GranuFoam.RTM. dressing or VeraFlo.RTM.
foam, both available from Kinetic Concepts, Inc. of San Antonio,
Tex.
[0041] The tissue interface 108 may be either hydrophobic or
hydrophilic. In an example in which the tissue interface 108 may be
hydrophilic, the tissue interface 108 may also wick fluid away from
a tissue site, while continuing to distribute negative pressure to
the tissue site. The wicking properties of the tissue interface 108
may draw fluid away from a tissue site by capillary flow or other
wicking mechanisms. An example of a hydrophilic foam is a polyvinyl
alcohol, open-cell foam such as V.A.C. WhiteFoam.RTM. dressing
available from Kinetic Concepts, Inc. of San Antonio, Tex. Other
hydrophilic foams may include those made from polyether. Other
foams that may exhibit hydrophilic characteristics include
hydrophobic foams that have been treated or coated to provide
hydrophilicity.
[0042] The tissue interface 108 may further promote granulation at
a tissue site when pressure within the sealed therapeutic
environment is reduced. For example, any or all of the surfaces of
the tissue interface 108 may have an uneven, coarse, or jagged
profile that can induce microstrains and stresses at a tissue site
if negative pressure is applied through the tissue interface
108.
[0043] In some embodiments, the tissue interface 108 may be
constructed from bioresorbable materials. Suitable bioresorbable
materials may include, without limitation, a polymeric blend of
polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric
blend may also include without limitation polycarbonates,
polyfumarates, and capralactones. The tissue interface 108 may
further serve as a scaffold for new cell-growth, or a scaffold
material may be used in conjunction with the tissue interface 108
to promote cell-growth. A scaffold is generally a substance or
structure used to enhance or promote the growth of cells or
formation of tissue, such as a three-dimensional porous structure
that provides a template for cell growth. Illustrative examples of
scaffold materials include calcium phosphate, collagen, PLA/PGA,
coral hydroxy apatites, carbonates, or processed allograft
materials.
[0044] In some embodiments, the cover 106 may provide a bacterial
barrier and protection from physical trauma. The cover 106 may also
be constructed from a material that can reduce evaporative losses
and provide a fluid seal between two components or two
environments, such as between a therapeutic environment and a local
external environment. The cover 106 may be, for example, an
elastomeric film or membrane that can provide a seal adequate to
maintain a negative pressure at a tissue site for a given
negative-pressure source. The cover 106 may have a high
moisture-vapor transmission rate (MVTR) in some applications. For
example, the MVTR may be at least 300 g/m{circumflex over ( )}2 per
twenty-four hours in some embodiments. In some example embodiments,
the cover 106 may be a polymer drape, such as a polyurethane film,
that is permeable to water vapor but impermeable to liquid. Such
drapes typically have a thickness in the range of 25-50 microns.
For permeable materials, the permeability generally should be low
enough that a desired negative pressure may be maintained.
[0045] An attachment device may be used to attach the cover 106 to
an attachment surface, such as undamaged epidermis, a gasket, or
another cover. The attachment device may take many forms. For
example, an attachment device may be a medically-acceptable,
pressure-sensitive adhesive that extends about a periphery, a
portion, or an entire sealing member. In some embodiments, for
example, some or all of the cover 106 may be coated with an acrylic
adhesive having a coating weight between 25-65 grams per square
meter (g.s.m.). Thicker adhesives, or combinations of adhesives,
may be applied in some embodiments to improve the seal and reduce
leaks. Other example embodiments of an attachment device may
include a double-sided tape, paste, hydrocolloid, hydrogel,
silicone gel, or organogel.
[0046] A controller, such as the controller 110, may be a
microprocessor or computer programmed to operate one or more
components of the therapy system 100, such as the negative-pressure
source 104. In some embodiments, for example, the controller 110
may be a microcontroller, which generally comprises an integrated
circuit containing a processor core and a memory programmed to
directly or indirectly control one or more operating parameters of
the therapy system 100. Operating parameters may include the power
applied to the negative-pressure source 104, the pressure generated
by the negative-pressure source 104, or the pressure distributed to
the tissue interface 108, for example. The controller 110 is also
preferably configured to receive one or more input signals, such as
a feedback signal, and programmed to modify one or more operating
parameters based on the input signals.
[0047] Sensors, such as the pressure sensor 122 or the electric
sensor 124, are generally known in the art as any apparatus
operable to detect or measure a physical phenomenon or property,
and generally provide a signal indicative of the phenomenon or
property that is detected or measured. For example, the pressure
sensor 122 and the electric sensor 124 may be configured to measure
one or more operating parameters of the therapy system 100. In some
embodiments, the pressure sensor 122 may be a transducer configured
to measure pressure in a pneumatic pathway and convert the
measurement to a signal indicative of the pressure measured. In
some embodiments, for example, the pressure sensor 122 may be a
piezoresistive strain gauge. The electric sensor 124 may optionally
measure operating parameters of the negative-pressure source 104,
such as the voltage or current, in some embodiments. Preferably,
the signals from the pressure sensor 122 and the electric sensor
124 are suitable as an input signal to the controller 110, but some
signal conditioning may be appropriate in some embodiments. For
example, the signal may need to be filtered or amplified before it
can be processed by the controller 110. Typically, the signal is an
electrical signal, but may be represented in other forms, such as
an optical signal.
[0048] The container 112 is representative of a container,
canister, pouch, or other storage component, which can be used to
manage exudates and other fluids withdrawn from a tissue site. In
many environments, a rigid container may be preferred or required
for collecting, storing, and disposing of fluids. In other
environments, fluids may be properly disposed of without rigid
container storage, and a re-usable container could reduce waste and
costs associated with negative-pressure therapy.
[0049] The solution source 114 may also be representative of a
container, canister, pouch, bag, or other storage component, which
can provide a solution for instillation therapy. Compositions of
solutions may vary according to a prescribed therapy, but examples
of solutions that may be suitable for some prescriptions include
hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based
solutions, biguanides, cationic solutions, and isotonic
solutions.
[0050] In operation, the tissue interface 108 may be placed within,
over, on, or otherwise proximate to a tissue site. The cover 106
may be placed over the tissue interface 108 and sealed to an
attachment surface near the tissue site. For example, the cover 106
may be sealed to undamaged epidermis peripheral to a tissue site.
Thus, the dressing 102 can provide a sealed therapeutic environment
proximate to a tissue site, substantially isolated from the
external environment, and the negative-pressure source 104 can
reduce the pressure in the sealed therapeutic environment. Negative
pressure applied across the tissue site through the tissue
interface 108 in the sealed therapeutic environment can induce
macrostrain and microstrain in the tissue site, as well as remove
exudates and other fluids from the tissue site, which can be
collected in container 112. In some embodiments, negative pressure
may be applied intermittently or periodically, with intervals of
negative pressure and intervals of venting or positive
pressure.
[0051] During negative-pressure intervals, negative pressure can
actuate the instillation actuator 118, which can operate the dosing
chamber 120. For example, in some embodiments, the instillation
actuator 118 can expand the dosing chamber 120 during a
negative-pressure interval, lowering pressure in the dosing chamber
120 and drawing instillation solution into the dosing chamber 120
from the solution source 114 through a first check valve, which can
substantially prevent return of the instillation solution from the
dosing chamber 120 to the solution source 114. During a subsequent
venting interval, the instillation actuator 118 can contract the
dosing chamber 120, increasing the pressure in the dosing chamber
120 and expelling instillation solution from the dosing chamber 120
through a second check valve to the dressing 102. The second check
valve can substantially prevent return of the instillation solution
(as well as exudate) to the dosing chamber 120. The instillation
solution may dwell at the tissue site for the duration of the
venting interval, and then be removed from the tissue site and
drawn into the container 112 during a subsequent negative-pressure
interval. A filter can be disposed between the instillation
actuator 118 and the dressing 102 to prevent contamination of the
instillation actuator 118. For example, the filter may be a
bacterial filter configured to remove bacteria from fluid flowing
through the filter from the dressing 102.
[0052] FIG. 2 is a schematic diagram illustrating additional
details of a distribution system 200 that may be associated with
some example embodiments of the instillation pump 116. In the
example embodiment of FIG. 2, the dosing chamber 120 may be a
bellows, flexible bladder, or other chamber with flexible side
walls suitable for holding instillation solution. In other example
embodiments, the dosing chamber 120 may comprise a rigid wall with
a reciprocating piston. The dosing chamber 120 of FIG. 2 generally
comprises opposing fixation points 205, a fluid inlet 210, and a
fluid outlet 215.
[0053] As illustrated in FIG. 2, a first check valve 220 may be
fluidly coupled to the fluid inlet 210. The first check valve 220
may be fluidly coupled to a first fluid conductor 230. An interface
235 may also be coupled to the first fluid conductor 230 in some
embodiments. The interface 235 is generally configured to connect
the first fluid conductor 230 to a solution source, such as the
solution source 114. For example, in some embodiments, the
interface 235 may be a connector configured to puncture a bag or
port, such as a spike connector. In other embodiments, the first
fluid conductor 230 may be directly coupled to the solution source
114.
[0054] The fluid outlet 215 may be fluidly coupled to a second
check valve 240, which may be fluidly coupled to a second fluid
conductor 245. The second fluid conductor 245 may be fluidly
coupled to a fluid port 250 in some embodiments. In some
embodiments, the second fluid conductor 245 may have a constriction
255 between the second check valve 240 and the fluid port 250.
[0055] The fluid port 250 is generally configured to fluidly couple
the second fluid conductor 245 to another distribution component,
such as the dressing 102. For example, the fluid port 250 may be a
dressing interface, or may be configured to be coupled to a
dressing interface in some embodiments.
[0056] A third fluid conductor 260 may also be fluidly coupled to
the fluid port 250. In some embodiments, the third fluid conductor
260 may be directly coupled to the fluid port 250, as illustrated
in the example of FIG. 2. In other embodiments, the third fluid
conductor 260 may be indirectly coupled to the fluid port 250. For
example, the third fluid conductor 260 may be fluidly coupled to
the second fluid conductor 245, which can indirectly couple the
third fluid conductor 260 to the fluid port 250. In yet other
examples, the distribution system may comprise a second fluid port,
and the third fluid conductor 260 may be fluidly coupled to the
second fluid port.
[0057] A fluid fitting 265 can be coupled to the third fluid
conductor 260 opposite the fluid port 250. The fluid fitting 265 is
generally configured to fluidly couple the third fluid conductor
260 to an instillation actuator, such as the instillation actuator
118. A bacterial filter 270 can also be coupled to the third fluid
conductor 260 between the fluid port 250 and the fluid fitting
265.
[0058] FIG. 3A is a schematic diagram illustrating additional
details that may be associated with some embodiments of the
instillation pump 116 during a negative-pressure interval. FIG. 3B
is a schematic diagram illustrating additional details that may be
associated with some embodiments of the instillation pump 116
during a venting interval. FIG. 3A and FIG. 3B also illustrate an
example embodiment of the instillation actuator 118 operatively
coupled to the distribution system 200 of FIG. 2.
[0059] The instillation actuator 118 may comprise one or more
pneumatic cylinders in some embodiments. In general, a pneumatic
cylinder may comprise a piston contained within a piston chamber of
a housing. The piston may be a disc, cylinder, diaphragm, or other
working member that can provide a fluid barrier, and pressure
changes in the piston chamber may move the piston within the piston
chamber. Movement within the chamber is typically a rectilinear
motion between two opposing extremities. A pneumatic cylinder also
generally includes a low-friction fluid seal between the piston and
side walls of the piston chamber. The fluid seal may be attached to
the side walls of the piston chamber, allowing relative movement
between the piston and the fluid seal, or the fluid seal may be
attached to the piston, allowing relative movement between the
fluid seal and the piston chamber. The fluid seal and the piston
effectively partition the piston chamber into a working chamber and
an ambient chamber. The working chamber can be fluidly coupled to a
fluid port in the housing, through which a working fluid can be
transferred to and from the working chamber. In some embodiments, a
pneumatic cylinder may also include a spring return to bias the
piston to a neutral position. For example, a spring may be coupled
to the piston in the working chamber, the ambient chamber, or
both.
[0060] For example, as illustrated in the example of FIG. 3A and
FIG. 3B, some embodiments of the instillation actuator 118 may
comprise a dosing piston 305 contained within a piston chamber of a
housing 310. A seal 315 can partition the piston chamber into an
ambient chamber 320 and a working chamber 325. A fluid port 330 may
be fluidly coupled to the working chamber 325. In some embodiments,
a return spring 335 may also be disposed in the working chamber 325
and coupled to a first side of the dosing piston 305. The dosing
piston 305 may also be coupled to or otherwise comprise a dosing
rod 340 coupled to a second side. A working fluid entering the
working chamber 325 through the fluid port 330 can cause pressure
changes in the working chamber 325 and a resulting movement of the
dosing piston 305 between a first position and a second
position.
[0061] In some embodiments, the instillation actuator 118 may
additionally comprise a clamping piston 345, and the housing 310
may further comprise or define a second piston chamber in which the
clamping piston 345 may be disposed. A second low-friction seal 350
may be disposed in the second piston chamber between the housing
310 and the clamping piston 345, dividing the second piston chamber
into an ambient chamber 355 and a working chamber 360. The working
chamber 360 may be fluidly coupled to the fluid port 330 in some
embodiments. For example, the working chamber 360 may be fluidly
coupled to the fluid port 330 through the working chamber 325, as
illustrated in the example of FIG. 3A and FIG. 3B. In other
embodiments, the working chamber 360 may be fluidly coupled to a
second fluid port. In some embodiments, a return spring 365 may be
disposed in the working chamber 360 and coupled to a first side of
the clamping piston 345. A clamping rod 370 may be coupled to a
second side of the clamping piston 345. The clamping rod 370 may
pass through the housing 310 and be coupled to a clamp 375 outside
the housing 310. The clamp 375 generally has an open state and a
closed state. A working fluid entering the working chamber 360
through the fluid port 330 can cause pressure changes in the
working chamber 360 and a resulting movement of the clamping piston
345 between a first position and a second position. The movement of
the clamping piston 345 can be transferred to the clamp 375 through
the clamping rod 370, opening and closing the clamp 375. For
example, the first position of the clamping piston 345 may
correspond to the closed state of the clamp 375 and the second
position of the clamping piston 345 may correspond to the open
state of the clamp 375.
[0062] The instillation actuator 118 may be fastened to the
distribution system 200. For example, some embodiments of the
instillation actuator 118 may comprise one or more attachment arms,
such as an attachment arm 380, which can be releasably fastened to
the distribution system 200. In some embodiments, a first end of
the attachment arm 380 may be rigidly coupled to the housing 310.
As illustrated in the example of FIG. 3A and FIG. 3B, a second end
of the attachment arm 380 may be fastened to the dosing chamber 120
adjacent to the fluid inlet 210. The instillation actuator 118 or
the attachment arm 380 preferably comprises one or more fasteners,
which can be readily coupled to and uncoupled from the distribution
system 200 without compromising the integrity of the instillation
actuator 118 or the distribution system 200. Suitable fasteners may
include retaining rings, snap rings, or terry clips, for example.
In some embodiments, the fastener may be configured to attach
directly to the dosing chamber 120, and relative motion between the
dosing chamber 120 and the housing 310 may additionally be
constrained by a fixation point 205.
[0063] The dosing piston 305 may be similarly fastened to the
distribution system 200. For example, in the example embodiment of
FIG. 3A and FIG. 3B, the dosing rod 340 of the dosing piston 305
may be fastened to the dosing chamber 120 adjacent to the fluid
outlet 215.
[0064] The clamp 375 may be also be operably coupled to the
distribution system 200 in some embodiments. For example, the
second fluid conductor 245 may be positioned within or through the
clamp 375. In some examples, the fluid constriction 255 may be
positioned within or through the clamp 375, and the clamp 375 may
be supported from above or below by suitable fasteners.
[0065] The fluid port 330 may be fluidly coupled to the fluid port
250. For example, the fluid fitting 265 may be coupled to the fluid
port 330, providing a fluid path between the fluid port 330 and the
fluid port 250 through the third fluid conductor 260.
[0066] In operation, the fluid port 250 may also be fluidly coupled
to a negative-pressure source, such as the negative-pressure source
104, and the fluid inlet 210 may be fluidly coupled to a source of
instillation solution, such as the solution source 114. In some
embodiments the fluid port 250 may be indirectly coupled to a
negative-pressure source through other distribution components,
such as a dressing. For example, the fluid port 250 may be coupled
to the dressing 102.
[0067] During a negative-pressure interval, negative pressure
applied to the fluid port 250 may be distributed to the fluid
outlet 215 and to the fluid port 330. A fluid constriction, such as
the fluid constriction 255, between the fluid outlet 215 and the
fluid port 250 can allow pressure in the working chamber 360 to
decrease at a faster rate than pressure in the dosing chamber
120.
[0068] If negative pressure in the working chamber 360 exceeds a
first negative-pressure threshold, the pressure differential across
the clamping piston 345 can overcome the force of the return spring
365, moving the clamping piston 345 to compress the return spring
365 in the working chamber 360 as illustrated in the example of
FIG. 3A. Movement of the clamping piston 345 may be transferred to
the clamp 375 through the clamping rod 370, closing the clamp 375
on the second fluid conductor 245, also illustrated in the example
of FIG. 3A. In the closed state, the clamp 375 preferably prevents
fluid transfer between the dosing chamber 120 and the fluid port
250 through the second fluid conductor 245.
[0069] If negative pressure in the working chamber 325 exceeds a
second negative-pressure threshold, the pressure differential
across the dosing piston 305 can overcome the force of the return
spring 335, moving the dosing piston 305 to compress the return
spring 335 in the working chamber 325 as illustrated in the example
of FIG. 3A. In some embodiments, the second negative-pressure
threshold may be greater than the first negative-pressure
threshold, so that the clamp 375 can be closed before the dosing
piston 305 moves. In other example embodiments, the second
negative-pressure threshold may be substantially equal to the first
negative-pressure threshold. Movement of the dosing piston 305 may
be transferred to the dosing chamber 120. For example, the dosing
piston 305 may move the dosing rod 340. If the fluid inlet 210 is
held static by the attachment arm 380 coupled to the adjacent
fixation point 205, as in the example of FIG. 3A, movement of the
dosing rod 340 can move the fluid outlet 215 relative to the fluid
inlet 210, expanding the working volume of the dosing chamber 120,
as also illustrated in the example of FIG. 3A.
[0070] The second check valve 240 may be normally closed, creating
a closed system of the solution source 114 and the dosing chamber
120. Expansion of the dosing chamber 120 reduces the pressure in
the dosing chamber under such conditions, creating a pressure
gradient between the solution source 114 and the dosing chamber 120
that can move instillation solution from the solution source 114
through the first check valve 220 into the dosing chamber 120.
Additionally or alternatively, in some example configurations
gravity may also move instillation solution from the solution
source 114 into the dosing chamber 120, particularly if the
solution source 114 is elevated above the dosing chamber 120.
[0071] The amount of fluid transferred from the solution source 114
to the dosing chamber 120 can be calibrated by modifying certain
system parameters. For example, the size of the piston chamber or
the spring constant of the return spring 335 can be modified to
change the stroke length of the dosing piston 305 in some
embodiments. Alternatively or additionally, the size of the dosing
chamber 120 may be increased or decreased according to therapeutic
needs. In yet other examples, the dosing may be controlled or
modified by the controller 110. For example, the controller 110 may
be programmed to change the frequency or duration of venting
intervals or negative-pressure intervals, or both, which can
control dosing and the dwell time of instillation fluid.
[0072] During a venting interval, negative pressure in the working
chamber 360 can decrease until clamp 375 opens, as illustrated in
the example of FIG. 3B. For example, if the first negative-pressure
threshold exceeds the negative pressure in the working chamber 360,
the force of the return spring 365 can overcome the pressure
differential across the clamping piston 345, allowing the clamping
piston 345 to return to a neutral position and opening the clamp
375.
[0073] If the second negative-pressure threshold exceeds the
negative pressure in the working chamber 325, the force of the
return spring 335 can exceed the pressure differential across the
dosing piston 305, allowing the dosing piston 305 return to a
neutral position, as illustrated in the example of FIG. 3B.
Movement of the dosing piston 305 to the neutral position may be
transferred to the dosing chamber 120. For example, the dosing
piston 305 may move the dosing rod 340. If the fluid inlet 210 is
held static by the attachment arm 380 coupled to the adjacent
fixation point 205, as in the example of FIG. 3B, movement of the
dosing rod 340 can move the fluid outlet 215 relative to the fluid
inlet 210, contracting the working volume of the dosing chamber
120, as also illustrated in the example of FIG. 3B.
[0074] The first check valve 220 may be normally closed, and
contracting the dosing chamber 120 can increase the pressure in the
dosing chamber 120 under such conditions, creating a pressure
gradient between the dosing chamber 120 and the fluid port 250 that
can move instillation solution from the dosing chamber 120 through
the second check valve 240 into the second fluid conductor 245. The
first check valve 220 can prevent instillation solution from being
returned to the solution source 114 as the pressure increases. In
some embodiments, the instillation solution can be delivered to the
dressing 102 through the fluid port 250. Instillation solution may
also be transferred from the second fluid conductor 245 to the
third fluid conductor in some embodiments. For example, a large
dose of instillation solution may be at least partially (and
temporarily) transferred to the fluid conductor 260 if the dose
exceeds the capacity of the dressing 102. The bacterial filter 270
can prevent contamination of the instillation actuator 118.
[0075] FIG. 4 is a schematic diagram illustrating additional
details of another example distribution system 400 that may be
associated with some embodiments of the instillation pump 116. In
the example embodiment of FIG. 4, the dosing chamber 120 may
comprise a housing and a rolling diaphragm or other flexible
barrier. For example, as illustrated in the embodiment of FIG. 4,
the dosing chamber 120 may comprise a housing 405 and a rolling
diaphragm 410. In some embodiments, the housing 405 may be a
half-cylinder, and is preferably sufficiently rigid to maintain its
shape in operation. The rolling diaphragm 410 may comprise a flange
415, which can be coupled to the housing 405 to provide a seal
across the housing 405, defining a pressure vessel having a
variable volume and flexible, moving side-walls. The dosing chamber
120 may additionally comprise one or more fixation points 417, a
return spring 420, a fluid inlet 425, and a fluid outlet 430.
[0076] As illustrated in FIG. 4, a first check valve 435 may be
fluidly coupled to the fluid inlet 425. The first check valve 435
may be fluidly coupled to a first fluid conductor 440. An interface
445 may also be coupled to the first fluid conductor 440 in some
embodiments. The interface 445 is generally configured to connect
the first fluid conductor 440 to a solution source, such as the
solution source 114. For example, in some embodiments, the
interface 445 may be a connector configured to puncture a bag or
port, such as a spike connector. In other embodiments, the first
fluid conductor 440 may be directly coupled to the solution source
114.
[0077] The fluid outlet 430 may be fluidly coupled to a second
check valve 450, which may be fluidly coupled to a second fluid
conductor 455. The second fluid conductor 455 may be fluidly
coupled to a fluid port 460 in some embodiments. In some
embodiments, the second fluid conductor 455 may have a constriction
465 between the second check valve 450 and the fluid port 460.
[0078] The fluid port 460 is generally configured to fluidly couple
the second fluid conductor 455 to another distribution component,
such as the dressing 102. For example, the fluid port 460 may be a
dressing interface, or may be configured to be coupled to a
dressing interface in some embodiments.
[0079] A third fluid conductor 470 may also be fluidly coupled to
the fluid port 460. In some embodiments, the third fluid conductor
470 may be directly coupled to the fluid port 460, as illustrated
in the example of FIG. 4. In other embodiments, the third fluid
conductor 470 may be indirectly coupled to the fluid port 460. For
example, the third fluid conductor 470 may be fluidly coupled to
the second fluid conductor 455, which can indirectly couple the
third fluid conductor 470 to the fluid port 460.
[0080] A fluid fitting 475 can be coupled to the third fluid
conductor 470 opposite the fluid port 460. The fluid fitting 475 is
generally configured to fluidly couple the third fluid conductor
470 to an instillation actuator, such as the instillation actuator
118. A bacterial filter 480 can also be coupled to the third fluid
conductor 470 between the fluid port 460 and the fluid fitting
475.
[0081] In some embodiments, the dosing chamber 120 may additionally
include a biasing element, such as the return spring 420, disposed
between the housing 405 and the rolling diaphragm 410 to bias the
rolling diaphragm 410 away from the housing 405.
[0082] FIG. 5A is a schematic diagram illustrating additional
details that may be associated with other example embodiments of
the instillation pump 116 during a negative-pressure interval. FIG.
5B is a schematic diagram illustrating additional details that may
be associated with other example embodiments of the instillation
pump 116 during a venting interval. FIG. 5A and FIG. 5B also
illustrate another example embodiment of the instillation actuator
118, operatively coupled to the distribution system 400 of FIG.
4.
[0083] The example instillation actuator 118 of FIG. 5A and FIG. 5B
may also comprise one or more pneumatic cylinders in some
embodiments. For example, some embodiments of the instillation
actuator 118 may comprise a housing 510 that can be coupled to the
housing 405, and the diaphragm 410 can partition the dosing chamber
120 from a working chamber 525 between the housing 510 and the
diaphragm 410. In some embodiments, the instillation actuator 118
may additionally comprise a piston (not shown) operably engaged to
the diaphragm 410, but the diaphragm 410 may effectively operate as
a piston in some embodiments. For example, the diaphragm 410 may be
sufficiently flexible to move under the influence of a pressure
differential across it, or may be directly engaged to a return
spring 535, as shown in the example of FIG. 5A and FIG. 5B.
[0084] A fluid port 530 may be fluidly coupled to the working
chamber 525. A working fluid entering the working chamber 525
through the fluid port 530 can cause pressure changes in the
working chamber 525 and a resulting movement of the diaphragm 410
between a first position and a second position.
[0085] In some embodiments, the instillation actuator 118 may
additionally comprise a clamping piston 545, and the housing 510
may further comprise or define a second piston chamber in which the
clamping piston 545 may be disposed. A low-friction seal 550 may be
disposed in the second piston chamber between the housing 510 and
the clamping piston 545, dividing the second piston chamber into an
ambient chamber 555 and a working chamber 560. The working chamber
560 may be fluidly coupled to the fluid port 530 in some
embodiments. For example, the working chamber 560 may be fluidly
coupled to the fluid port 530 through the working chamber 525, as
illustrated in the example of FIG. 5A and FIG. 5B. In other
embodiments, the working chamber 560 may be fluidly coupled to a
second fluid port. In some embodiments, a return spring 565 may be
disposed in the working chamber 560 and coupled to a first side of
the clamping piston 545. A clamping rod 570 may be coupled to a
second side of the clamping piston 545. The clamping rod 570 may
pass through the housing 510 and be coupled to a clamp 575 outside
the housing 510. The clamp 575 generally has an open state and a
closed state. A working fluid entering the working chamber 560
through the fluid port 530 can cause pressure changes in the
working chamber 560 and a resulting movement of the clamping piston
545 between a first position and a second position. The movement of
the clamping piston 545 can be transferred to the clamp 575 through
the clamping rod 570, opening and closing the clamp 575. For
example, the first position of the clamping piston 545 may
correspond to the closed state of the clamp 575 and the second
position of the clamping piston 545 may correspond to the open
state of the clamp 575.
[0086] The instillation actuator 118 may be operably coupled to the
distribution system 400. Some embodiments of the housing 510 may
comprise one or more fasteners, which can be releasably fastened to
the distribution system 400. For example, the housing 510 may be
configured to be threaded onto the dosing chamber 120 in some
embodiments. Additionally or alternatively, the instillation
actuator 118 may comprise one or more fasteners, which can be
readily coupled to and uncoupled from the dosing chamber 120
without compromising the integrity of the instillation actuator 118
or the dosing chamber 120. Suitable fasteners may include retaining
rings, snap rings, or terry clips, for example.
[0087] The clamp 575 may be also be operably coupled to the
distribution system 400 in some embodiments. For example, the
second fluid conductor 455 may be positioned within or through the
clamp 575. In some examples, the fluid constriction 465 may be
positioned within or through the clamp 575, and the clamp 575 may
be supported from above or below by suitable fasteners.
[0088] The fluid port 530 may be fluidly coupled to the fluid port
460. For example, the fluid fitting 475 may be coupled to the fluid
port 530, providing a fluid path between the fluid port 530 and the
fluid port 460 through the third fluid conductor 470.
[0089] In operation, the fluid port 460 may also be fluidly coupled
to a negative-pressure source, such as the negative-pressure source
104, and the fluid inlet 425 may be fluidly coupled to a source of
instillation solution, such as the solution source 114. In some
embodiments the fluid port 460 may be indirectly coupled to a
negative-source through other distribution components, such as a
dressing. For example, the fluid port 460 may be coupled to the
dressing 102.
[0090] During a negative-pressure interval, negative pressure
applied to the fluid port 460 may be distributed to the fluid
outlet 430 and to the fluid port 530. A fluid constriction, such as
the fluid constriction 465, between the fluid outlet 430 and the
fluid port 460 can allow pressure in the working chamber 525 to
decrease at a faster rate than pressure in the dosing chamber
120.
[0091] If negative pressure in the working chamber 560 exceeds a
first negative-pressure threshold, the pressure differential across
the clamping piston 545 can overcome the force of the return spring
565, moving the clamping piston 545 to compress the return spring
565 in the working chamber 560 as illustrated in the example of
FIG. 5A. Movement of the clamping piston 545 may be transferred to
the clamp 575 through the clamping rod 570, closing the clamp 575
on the second fluid conductor 455, also illustrated in the example
of FIG. 5A. In the closed state, the clamp 575 preferably prevents
fluid transfer between the dosing chamber 120 and the fluid port
460 through the second fluid conductor 455. The first position and
the second position of the claim 575 may vary, depending on the
diameter and wall thickness of the second fluid conductor 455, for
example.
[0092] If negative pressure in the working chamber 525 exceeds a
second negative-pressure threshold, the pressure differential
across the diaphragm 410 can overcome the force of the return
spring 535, moving the diaphragm 410 to compress the return spring
535 in the working chamber 525 as illustrated in the example of
FIG. 5A. In some embodiments, the second negative-pressure
threshold may be greater than the first negative-pressure
threshold, so that the clamp 575 can be closed before the diaphragm
410 moves. In other example embodiments, the second
negative-pressure threshold may be substantially equal to the first
negative-pressure threshold. Movement of the diaphragm 410 against
the return spring 535 can also expand the working volume of the
dosing chamber 120, as also illustrated in the example of FIG.
5A.
[0093] The second check valve 450 may be normally closed, creating
a closed system of the solution source 114 and the dosing chamber
120. Expansion of the dosing chamber 120 reduces the pressure in
the dosing chamber 120 under such conditions, creating a pressure
gradient between the solution source 114 and the dosing chamber 120
that can move instillation solution from the solution source 114
through the first check valve 435 into the dosing chamber 120.
[0094] The amount of fluid transferred from the solution source 114
to the dosing chamber 120 can be calibrated by modifying certain
system parameters. For example, the size of the dosing chamber 120
or the spring constant of the return spring 420 can be modified to
change the stroke length of the diaphragm 410 in some embodiments.
Alternatively or additionally, the size of the dosing chamber 120
may be increased or decreased according to therapeutic needs.
[0095] During a venting interval, negative pressure in the working
chamber 560 can decrease until clamp 575 opens, as illustrated in
the example of FIG. 5B. For example, if the first negative-pressure
threshold exceeds the negative pressure in the working chamber 560,
the force of the return spring 565 can overcome the pressure
differential across the clamping piston 545, allowing the clamping
piston 545 to return to a neutral position and opening the clamp
575.
[0096] If the second negative-pressure threshold exceeds the
negative pressure in the working chamber 525, the force of the
return spring 535 can exceed the pressure differential across the
diaphragm 410, moving the diaphragm 410 and contracting the working
volume of the dosing chamber 120, as also illustrated in the
example of FIG. 5B.
[0097] The first check valve 435 may be normally closed, and
contracting the dosing chamber 120 can increase the pressure in the
dosing chamber under such conditions, creating a pressure gradient
between the dosing chamber 120 and the fluid port 460 that can move
instillation solution from the dosing chamber 120 through the
second check valve 450 into the second fluid conductor 455. The
first check valve 435 can prevent instillation solution from being
returned to the solution source 114 as the pressure increases. In
some embodiments, the instillation solution can be delivered to the
dressing 102 through the fluid port 460. The bacterial filter 480
can prevent contamination of the instillation actuator 118.
[0098] The systems, apparatuses, and methods described herein may
provide significant advantages. For example, some therapy systems
are known to provide intermittent negative-pressure therapy modes,
and the instillation pump 116 can leverage such modes to deliver
therapeutic fluids without substantially modifying the therapy
system. The instillation pump 116 can also reduce the disposable
footprint of the therapy system 100 while providing cost-effective
delivery of therapeutic fluids to tissue sites. Much of the
mechanical system, such as the instillation actuator 118, can be
used by more than one patient. For example, the instillation pump
116 can provide a continuous fluid pathway that can be separated
from a mechanical actuator, allowing another fluid pathway to be
installed. Tubing, valves, fluid chambers, and associated
components can be removed in some embodiments. The combined
assembly can also provide all pressure seals and fitments to allow
disposable elements to be installed and to maintain actuation
pressure within a pressure chamber. The instillation pump 116 can
be readily attached to a dressing and solution source, which can be
a significant feature for patients and care providers outside of a
medical facility.
[0099] The disposable elements can be combined with the mechanical
elements in a variety of different ways to provide therapy. For
example, in some embodiments, the disposable and mechanical systems
can be combined inline, externally mounted, or internally
mounted.
[0100] While shown in a few illustrative embodiments, a person
having ordinary skill in the art will recognize that the systems,
apparatuses, and methods described herein are susceptible to
various changes and modifications. For example, certain features,
elements, or aspects described in the context of one example
embodiment may be omitted, substituted, or combined with features,
elements, and aspects of other example embodiments. Moreover,
descriptions of various alternatives using terms such as "or" do
not require mutual exclusivity unless clearly required by the
context, and the indefinite articles "a" or "an" do not limit the
subject to a single instance unless clearly required by the
context. Components may be also be combined or eliminated in
various configurations for purposes of sale, manufacture, assembly,
or use. For example, in some configurations the dressing 102, the
container 112, or both may be eliminated or separated from other
components for manufacture or sale. In other example
configurations, the controller 110 may also be manufactured,
configured, assembled, or sold independently of other
components.
[0101] The appended claims set forth novel and inventive aspects of
the subject matter described above, but the claims may also
encompass additional subject matter not specifically recited in
detail. For example, certain features, elements, or aspects may be
omitted from the claims if not necessary to distinguish the novel
and inventive features from what is already known to a person
having ordinary skill in the art. Features, elements, and aspects
described herein may also be combined or replaced by alternative
features serving the same, equivalent, or similar purpose without
departing from the scope of the invention defined by the appended
claims.
* * * * *